Nujiangefolin A exhibits significant anti-inflammatory activity by inhibiting the production of nitric oxide (NO) in lipopolysaccharide (LPS)-stimulated microglial cells. This property makes it a potential candidate for research into neurodegenerative diseases where neuroinflammation plays a key role, such as Alzheimer's and Parkinson’s disease. Its ability to modulate inflammatory pathways suggests possible development as a therapeutic agent or lead compound in central nervous system disorders. Additionally, due to its natural origin and structural complexity, it serves as a valuable molecule for structure-activity relationship studies in anti-inflammatory drug discovery.